Solute carrier family 2, facilitated glucose transporter member 1 (GLUT1) and DNA (GLUT1/DNA)

The concept of targeting hyperactive cancer cell glucose metabolism and intra-nuclear DNA refers to a dual-therapeutic strategy most notably exemplified by the drug glufosfamide. This approach exploits the Warburg effect, where malignant cells exhibit significantly increased glucose uptake and aerobic glycolysis to support rapid proliferation. By conjugating a cytotoxic agent, such as an alkylating mustard, to a glucose molecule, the therapy is selectively shuttled into cancer cells via overexpressed glucose transporters like GLUT1. Once inside the cell, the cytotoxic component targets the intra-nuclear DNA, inducing lethal structural damage and inhibiting replication. This mechanism aims to increase the therapeutic index of traditional chemotherapy by concentrating the DNA-damaging 'warhead' within metabolically active tumor cells while sparing healthy tissues with lower glucose demands.

Other names

Warburg effect and genomic DNAGlucose transporter 1 and nuclear DNAHyperactive glycolysis and DNAGLUT1 and DNA alkylation target

Glufosfamide acts as a prodrug where the glucose moiety targets the hyperactive glucose transporters (primarily GLUT1) overexpressed in cancer cells (Warburg effect). Once internalized, the ifosfamide mustard warhead is released and migrates to the nucleus to alkylate intra-nuclear DNA, causing cross-linking and cell death.